97 articles - From Friday Mar 07 2025 to Friday Mar 14 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Am J Gastroenterol |
|---|
ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. Extensive high-quality data from US populations regarding GPMC management are lacking, but continue to accrue, and the quality of evidence for the recommendations presented herein should be interpreted with this dynamic context in mind. The GPMC research and education agendas are broad and include high-quality prospective studies evaluating opportunistic endoscopic screening for GC/GPMC, refined delineation of what constitutes "high-risk" populations, development of novel biomarkers, alignment of best practices, implementation of training programs for improved GPMC/GC detection, and evaluation of the impact of these interventions on GC incidence and mortality in the US. |
| Gastroenterology |
Optimizing Bowel Preparation Quality for Colonoscopy: Consensus Recommendations by the US Multi-Society Task Force on Colorectal Cancer. We suggest the adjunctive use of oral simethicone for bowel preparation before colonoscopy. Routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and at the level of the endoscopy unit is also recommended, with a target of >90% for both rates. |
| Gastrointest Endosc |
Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on Colorectal Cancer. We suggest the adjunctive use of oral simethicone for bowel preparation before colonoscopy. Routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and at the level of the endoscopy unit is also recommended, with a target of >90% for both rates. |
| Gut |
British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer. The physical, emotional and financial costs to individuals, their families and society from cancer therapy can be considerable. Identifying and signposting affected patients who require specialist services is the role of al clinicians. Progress in the treatment of cancer increasingly means that patients require expert, multidisciplinary supportive care providing effective and safe treatment at every stage of the cancer journey. Development of such expertise should be prioritised as should the education of health professionals and the public in what, when and how acute and chronic gastrointestinal symptoms and complications should be managed. |
meta-analyses and systematic reviews
| Am J Gastroenterol |
|---|
IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials. IL-23p19 antagonists are probably more efficacious and safer than ustekinumab in patients with moderate-to-severe CD in patients with prior biologic exposure, but not in biologic-naïve patients. |
| Gastrointest Endosc |
Comparing the Safety and Efficacy of Overstitch, X-Tack, and Endoscopic Hand Suturing for Closure of Gastrointestinal Defects After Endoscopic Resection: A systematic review and Meta-Analysis. EHS and X-tack had lower adverse event rates than Overstitch. Future direct comparison studies would be needed to corroborate our findings. |
Endoscopists' knowledge, perceptions and attitudes toward the use of artificial intelligence in endoscopy: A systematic review. Concerns regarding the impact on clinical practice, costs and medicolegal considerations remain. Establishing robust regulatory frameworks is crucial to the integration of AI into endoscopy. |
| Hepatology |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up. Psychological co-morbidity and active disease have a cumulative adverse impact on IBD prognosis. |
Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. The infection incidence rate was 25.4 per 100 person-years (95% CI: 6.47-69.19), though the wide confidence interval limits conclusions on safety differences with monotherapy. These findings highlight the importance of preventive measures, careful patient selection, and rigorous monitoring to mitigate infection risks associated with ACT. |
Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population-Based Cohort Study. Our results suggest a significant corticosteroid-sparing effect of ileocaecal resection in Crohn's disease patients with high pre-operative use, indicating a beneficial outcome of earlier surgical intervention. Despite increasing use of biologics, pre-operative corticosteroid use was consistent over the study period. |
| Am J Gastroenterol |
Gastric Cancer Screening in the United States: A Review of Current Evidence, Challenges, and Future Perspectives. We further discuss the critical knowledge gaps and challenges in promoting gastric cancer screening in the United States. Dedicated research is urgently needed to enrich the US-based data on gastric cancer primary and secondary prevention to inform clinical practice and reduce gastric cancer-related morbidity and mortality in a cost and resource efficient manner. |
High Risk of Persistence and Risk of Dysplasia after Ultrashort Barrett's Diagnosis. The prevalence of persistent BE after index USBE is high, and there is a risk of developing dysplasia/neoplasia in persistent BE after USBE. We were unable to detect a difference in the risk of dysplasia/neoplasia between persistent BE after index USBE and BE ≥1cm on index endoscopy in a cohort of United States veterans. White race and Hispanic ethnicity are associated with persistent BE after index USBE and may be target demographics for surveillance. |
International, multicenter analysis of endoscopic full-thickness resection of duodenal neuroendocrine tumors. EFTR of dNET showed high technical success and R0 resection rates and very low rate of severe AEs. It could become endoscopic treatment of choice for dNET, at least for lesions not within proximity of the pylorus. |
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis. The mirikizumab 2-year integrated safety profile in patients with moderately to severely active UC was consistent across subgroups and with previous findings, without new significant safety concerns. |
Microscopic colitis and risk of venous thromboembolism: A nationwide matched cohort study. The results remained robust in sensitivity analyses. In this population-based study, individuals with MC had a 21% higher risk of VTE compared with reference individuals, equivalent to one extra VTE event for every 37 MC individuals followed for ten years. |
Minimum platelet count threshold for safe colonoscopic polypectomy: A large-scale propensity scored-matched analysis. The results obtained using IPTW were consistent. Patients with platelet counts < 90,000/μL exhibited significantly elevated rates of IPPB and DPPB, suggesting that maintaining platelet levels above this threshold may be crucial for ensuring the safety of colonic polypectomy. |
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study. At Weeks 12 and 52, a greater proportion of mirikizumab-treated patients versus placebo achieved IBDQ response, IBDQ remission, and clinically important improvement in physical and mental component summaries of SF-36 (all p<0.001). Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity versus placebo at Week 12 which were maintained at Week 52. |
| Clin Gastroenterol Hepatol |
CHOLECYSTECTOMY IS A RISK FACTOR FOR MICROSCOPIC COLITIS: A NATIONWIDE POPULATION-BASED MATCHED CASE CONTROL STUDY. Cholecystectomy is associated with an increased risk of subsequent MC. These findings have implications for surgeons and general practitioners and underscore the need for further research into the underlying association between bile-acid and microscopic colitis. |
Endoscopic En Bloc Versus Piecemeal Resection of Large Colonic Adenomas: carbon footprint post-hoc analysis of a randomized trial. ESD strategy for lesions over 25 mm could reduce the environmental impact by reducing the associated follow up colonoscopies and transports of patients. If P-EMR could be performed in local centers with similar quality, results would be in favor of local P-EMR. |
Intestinal Ultrasound Findings and Their Prognostic Value in Early Crohn's Disease - a Copenhagen IBD Cohort Study. Transmural remission is an achievable outcome target for many newly diagnosed Crohn's disease patients and is associated with a favorable clinical outcome, including sustained steroid-free clinical remission. Further, intestinal ultrasound findings at diagnosis predict future ileocecal resection. |
Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study. UPA was effective at inducing clinical and endoscopic remission in a real-world group of patients with CD, even with prior exposure to multiple prior advanced therapies. No new safety concerns were identified. |
Worsening disease severity as measured by I-SEE associates with decreased treatment response to topical steroids in eosinophilic esophagitis patients. I-SEE correlated with baseline features in a large EoE cohort, performed similarly in children and adults, and associated with post-treatment responses to tCS. These data support that I-SEE provides prognostic data and suggest that severe disease may benefit from intensive upfront management. |
| Endoscopy |
Real-time automated assessment of histological disease activity in patients with ulcerative colitis using single-wavelength endoscopy technology. At the per-patient level, overall diagnostic accuracy remained high at 94.4%, with only 2/36 underestimations compared with GBS. A novel SWE-CAD system demonstrated clinical accuracy of 94.4% at the per-patient level, potentially aiding physicians in interpreting subtle endoscopic abnormalities and paving the way to more individualized patient management. |
| Gastroenterology |
AI-driven Personalized Medicine: Transforming Clinical Practice in Inflammatory Bowel Disease. The future of IBD care lies in the AI-enabled "Endo-Histo-OMICs" integrative real-time approach, harmoniously fusing endoscopic, histological, and molecular data. Despite challenges in its adoption, this paradigm shift has the potential to refine risk stratification, improve therapeutic precision, and enable personalized interventions, ultimately advancing the implementation of precision medicine in routine clinical practice. |
Colon Cancer Screening, Surveillance, and Treatment: Novel AI driving strategies in the management of colon lesions. Moreover, CADx limited specificity and binary output underscore the necessity for explainable AI to gain endoscopists' trust. This review aims to explore the benefits, harms, and limitations of AI for colon cancer screening, surveillance, and treatment focusing on CADe and CADx systems for lesion detection and characterization, respectively, while addressing challenges in integrating these technologies into clinical practice. |
Mebeverine and the influence of labeling in adolescents with irritable bowel syndrome or functional abdominal pain-NOS: a 2x2 randomized, placebo-controlled trial. Mebeverine was ineffective in pediatric IBS and FAP-NOS treatment. However, a positive drug label significantly enhanced treatment outcomes compared to a blinded trial label. |
| Gut |
GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism. GPR171 deficiency promotes Th17 cell differentiation and causes lipid metabolism perturbation, contributing to intestinal inflammation in a FABP5-dependent manner. Target therapy (eg, BigLEN-Fc) represents a novel therapeutic approach for IBD treatment. |
| Hepatology |
AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database. AI-generated synthetic data derived from diffusion models can faithfully replicate complex hepatology datasets, maintain key clinical signals, and ensure strong privacy safeguards. This approach can help address data scarcity, enhance model generalizability, foster multi-institutional collaboration, and accelerate progress in hepatology research. |
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting hepatocellular carcinoma metastasis. Consequently, the metastatic capability of HCC was remarkably enhanced. Therapy targeting CAD may offer a promising approach to curb HCC metastasis by reducing tumor cells' metastatic potential and also shifting the tumor microenvironment towards a less pro-metastatic state. |
Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells. Finally, a positive correlation between PBX1, IL7R and HSC activation was identified in cirrhotic patients. Our data uncover a previously unappreciated role for PBX1 in HSC activation and provide proof-of-concept for targeting IL-7 signaling in the intervention of liver fibrosis. |
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: a post hoc analysis. These data highlight that terlipressin leads to an early, sustained increase in MAP, which is a key pharmacodynamic target for HRS-AKI reversal. |
| J Hepatol |
Circadian Control of Hepatic Ischemia/Reperfusion Injury via HSD17B13-Mediated Autophagy in Hepatocytes. Our study uncovers a pivotal role of hepatocyte BMAL1 in modulating circadian rhythms in HIRI via HSD17B13-mediated autophagy and offers a promising strategy for preventing and treating HIRI by targeting the BMAL1/HSD17B13 axis. Impact and implications This study unveils a pivotal role of the BMAL1/HSD17B13 axis in the circadian control of hepatic ischemia/reperfusion injury, providing new insights into the prevention and treatment of hepatic ischemia/reperfusion injury. The findings have scientific implications as they enhance our understanding of the circadian regulation of hepatic ischemia/reperfusion injury. Furthermore, clinically, this research offers opportunities for optimizing treatment strategies in hepatic ischemia/reperfusion injury by considering the timing of therapeutic interventions. |
Clinical and Pathophysiological Characteristics of Non-acute Decompensation of Cirrhosis. These findings are crucial for hepatologists and researchers in risk stratifying patients and optimizing transplant candidacy. Interventions targeting necroptosis and pyroptosis pathways may improve outcomes, providing a significant shift towards precision medicine in cirrhosis care. |
Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications. Two-thirds of patients with decompensated cirrhosis achieved recompensation twelve months post-SVR, leading to improved survival compared to those without recompensation, though still lower than in compensated patients. However, HCC risk remained unchanged in the recompensated cohort. |
Sour neuronal signalling attenuates macrophage mediated liver injury. Our findings provide new insights into the brain-liver axis and therapeutic perspectives for liver injury. This clinical trial was registered with the Chinese Clinical Trial Registry (ChiCTR2400088096) IMPACT AND IMPLICATIONS: ● This study clarified that sour stimuli, which is related to acid (low pH value), is at least partly responsible for reducing human and mouse liver ischemia and reperfusion injury through nerves, and confirmed the important role of brain-liver axis in liver ischemia and reperfusion injury.● This study found that brain-liver axis to increase liver ischemia-reperfusion injury through the secretion of TAFA2 protein, and proved that TAFA2 protein mediated liver ischemia-reperfusion injury through the recruitment and activation of macrophages.● This study found that CCR2 is the receptor for TAFA2 protein, and TAFA2 and CCL2 produce a different transcriptional profile by RNA sequencing. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
A comprehensive review of geriatric syndromes and assessment in older adults with inflammatory bowel diseases. Geriatric syndromes are prevalent and negatively impact older patients with IBD. Systematic assessment for their presence and multidisciplinary interventions to improve them are important to improve outcomes of older adults with IBD. |
| Gastroenterology |
| J Hepatol |
Hot and Cold Fibrosis: The Role of Serum Biomarkers to assess the Immune Mechanisms and ECM-Cell Interactions in Human Fibrosis. This article aims to explore the relationship between hot and cold fibrosis, the role of various types of collagens and their biologically active fragments in modulating the immune system, and how serological ECM biomarkers can help the understanding of the disease-relevant interactions between immune and mesenchymal cells in fibrotic tissues. Additionally, we draw lessons from immuno-oncology research in solid tumors to shed light on potential strategies for fibrosis treatment and highlight the advantage of having a "hot fibrotic environment" to treat fibrosis by enhancing collagen degradation through modulation of the immune system. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastroenterology |
| Gastrointest Endosc |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| J Hepatol |